NCT00299156View on ClinicalTrials.gov

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Interventions
DRUG

Clofarabine

Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00299156 - Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter